Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant [3]

International Journal of Neuropsychopharmacology

Volumn 9, Issue 4, 2006, Pages 493-494

  Corruble, E ^a   Buhl, C ^a   Esposito, D ^a   Schuster, J P ^a   Chouinard, V A ^a   Hardy, P ^a   Chouinard, G ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; OLANZAPINE; TACROLIMUS;

ADULT; CASE REPORT; CONCENTRATION RESPONSE; DELIRIUM; DELUSION; DRUG BLOOD LEVEL; GRAFT REJECTION; HALLUCINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; LETTER; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; PSYCHOSES, SUBSTANCE-INDUCED; TACROLIMUS;

EID: 33745541693     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006279     Document Type: Letter

References (4)

1. Beresford TP (2001). Neuropsychiatric complications of liver and other solid organ transplantation. Liver Transplantation 7 (Suppl.), 36-45.
2. Di Martini AF, Trzepacz PT, Davis SR (1996). Prospective study of FK506 side effects: anxiety or akathisia? Biological Psychiatry 40, 407-411.
3. Oliveiro PJ, Restrepo L, Mitchell SA, Tornatore CS, Frankel SR (2000). Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. American Journal of Neuroradiology 21, 1251-1254.
4. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, et al. (2001). Clinical utility of monitoring tacrolimus blood concentration in liver transplant patients. Journal of Clinical Pharmacology 41, 542-551.